Key facts
- BlueWhale Bio’s last known valuation is $52.0M (Oct 2025).
- It has raised $23.0M across 1 recorded rounds; the latest was Early Stage VC ($5.0M) in Oct 2025.
- Notable investors include Hillhouse Investment Group, Marshall Wace, Novalis LifeSciences, Danaher Ventures, Penn Center for Innovation.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BlueWhale Bio
Funding rounds
1 roundsAbout BlueWhale Bio
Developer of a cell-based therapeutic platform intended to overcome bottlenecks in gene therapy manufacturing. The company's platform utilizes Synecta Activation, which facilitates cell-derived nanoparticles to mimic the physiological activation of immune cells and superior cell quality achieved through a simplified workflow that is faster, robust, and cost-effective, enabling patients to attain effective cancer treatment plans.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2022
- Employees
- 31
- Website
- bluewhale.bio/
- Ownership
- Privately Held (backing)
BlueWhale Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BlueWhale Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BlueWhale Bio in its N-PORT filings yet. We sweep new filings monthly.